FOR MANY YEARS, cephalosporins as a class have been considered safe compounds for clinical use, with the possible exception of cephaloridine. Aside from hypersensitivity phenomena, cephalosporins produced only uncommon instances of clinically significant adverse effects. Comparatively speaking, with regard to adverseeffect profiles, a cephalosporin is a cephalosporin is a cephalosporin. For the most part, side-effect differentiation was attempted on the basis of the incidence of phlebitis with intravenous administration and the degree of pain encountered with intramuscular administration. Cephalothin apparently was responsible for a significantly greater degree of phlebitis and pain when administered intramuscularly than were other competitive cephalosporins, such as cephapirin and cephradine. However, this seemingly significant difference in side effects has become a mute point since the reformulation of cephalothin several years ago. Until recently, there was little difference in toxicity among the available cephalosporins. However, the advent of the newergeneration cephalosporins (i.e., cefotaxime, moxalactam, and cefoperazone) clearly has demonstrated that these cephalosporins differ significantly in side effect profiles, such that therapeutic decisions regarding their use must include consideration of the differences in adverse effects. That is not to say that the differences in clinical adverse effects are the sole consideration in selecting a cephalosporin, but that prior to the introduction of the newer-generation cephalosporins, little regard to comparable side effects was necessary in the cephalosporin-selection process.
Of the newer cephalosporins, specifically cefotaxime, moxalactam, and cefoperazone, the latter two agents have demonstrated adverse-effect profiles that distinguish them from cefotaxime. Although each of the newer cephalosporins has been associated with superinfection, there is no documentation demonstrating significant differences in superinfection potential or occurrence. Considerable noncomparative work and clinical impressions suggest that the overall prevalence of superinfection ranges between 1 and 10 percent for each of these agents.
Since moxalactaru's release for clinical use in the U.S., adverse effects of ever-increasing frequency and RANDALL A. PRINCE, Pharm.D., is Associate Professor, College of Pharmacy; L. ALBERTO VILLAR, M. D., is Associate in Medicine, Department of Internal Medicine, University of Iowa, Iowa City, IA 52242. severity have been encountered. Of particular importance has been the occurrence of coagulopathy. Although the mechanism for this adversity has yet to be delineated, some investigators are implicating strongly the presence of the methyltetrazolethio group. Once thought to occur only in elderly and debilitated patients, moxalactam coagulopathy is a risk for any patient, regardless of age or disease state. Anadditional problem that limits moxalactaru's clinical usefulness is the development of antabuse-like reactions (e.g., sweating, headache, hypotension). Not only are alcoholic beverages a threat, but also medication containing alcohol, such as certain preparations of theophylline, iron, and vitamins.
Cefoperazone is the most recently released of the new cephalosporins. There is a great deal of controversy concerning the side-effect profile of cefoperazone. Like moxalactam, it has a structural characteristic (a methyltetrazolethio group) thought to be associated with the development of coagulopathy. Although coagulopathies have not been encountered frequently, the potential for this side effect increases with widespread use of the agent. In addition, cefoperazone has been reported to cause antabuse-like reactions, thereby necessitating elimination of alcohol and alcohol-containing products during therapy. The most perplexing of the side effects noted with cefoperazone therapy is diarrhea. The experiences of various investigators differ considerably. Many centers have reported a prevalence of less than 5 percent, while certain other investigative groups have reported an occurrence as high as 48 percent. Since cefoperazone is excreted predominantly via the hepatic pathway, it has been suggested that bile composition may be disturbed and may account for the diarrhea. Preliminary investigations have not shown any significant disturbances in bile production or composition. With its widespread availability, it is imperative that clinicians be mindful that the true side-effect profile and the prevalence of side effects with cefoperazone are yet to be established.
It is fortunate that cefotaxime has not been associated with the side-effect profile of the other third-generation cephalosporins. Its use is not associated with coagulopat hies or antabuse-like reactions. It would appear to have a side-effect profile consistent with those of the earlier-generation cephalosporins, that is, hypersensitivity phenomena are a major concern with its use.
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the aid of comparative trials, we may find that superinfections differ significantly among the newergeneration cephalosporins, but those data have not been generated. At present, given the data available, cefotaxime appears to have the most favorable side-effect profile of the new-generation cephalosporins.
DRUG ABUSE BY OLDER ADULTS-WHO IS RESPONSIBLE?
by Peter P. Lamy WHEN ONE SPEAKS of drug abuse among the elderly, one rarely refers to the abuse of illicit drugs. While alcoholism (a real problem) and use of illicit drugs by the elderly does, indeed, exist, the vast majority of abuse concerns the misuse of legal drugs, both prescription and nonprescription.
Statistics show that elderly persons living in the community and having supplemental medical insurance receive approximately 18 prescriptions per year. Contrary to a general "feeling," the vast majority of noninstitutionalized older persons do not use psychotropic drugs, and those who do take them usually do not overuse them. Statistics also show that almost 70 percent of noninstitutionalized elderly use nonprescription drugs after self-diagnosis and self-selection of those drugs and, most often, neither the primary physician nor the pharmacist is aware of the use of these drugs.
Almost 30 percent of residents in nursing homes receive as many as 8 drugs daily; in some cases, the figure rises to 10 or 12 drugs. The drugs most often used in nursing homes are analgesics, cardiovascular agents, diuretics, laxatives, psychotropics, and vitamins.
Thus, it is quite apparent that, in order to reduce misuse of drugs by the elderly, we need to focus on the inappropriate use and overuse of prescription and nonprescription drugs.
Who Is Responsible?
While the use of six to eight drugs for one patient may, on the surface, appear to be abuse, this is not necessarily true. The patient with diabetes, hypertension, a urinary tract infection, arthritis, anemia secondary to the treatment of arthritis, and arrhythmias (which describe many of the elderly who are apparently fit and lead independent lives) may well need a high number of drugs to control and manage this multiple pathology. On the other hand, it has been shown that many elderly persons taking digoxin do not need it. The same holds true for diuretics, iron, psychotropic drugs, and many other agents. It is, therefore, often not easy to determine abuse and misuse; nevertheless, they occur probably more often than we care to admit.
Who is responsible?-federal policies and private insurance carriers, the pharmaceutical industry, educational institutions, the primary provider, and the patient himself.
Federal Policies and Private Insurance Carriers
Federal regulations mandate monthly drug regimen review, by pharmacists, of all federally financed patients in skilled nursing facilities. Moreover, judging this activity to be both cost-efficient and of patient benefit, the government intends to extend this requirement to residents in intermediate care facilities. Yet, this must remain a less-than-optimal activity as long as there are no proper reimbursement policies and as long as the degree of responsibility is not matched by a corresponding authority.
Furthermore, drug misuse and overuse could be reduced if the potential were to be recognized for pharmacists to take a more active role in preventive care (both primary and secondary) by bringing to the attention of the primary physician the problems the elderly may face, before these problems become serious medical disorders. It is essential, too, that pharmacists enter strongly into the field of home health care. An example illustrates the need for this step.
An 81-year-old, white female was hospitalized with massive cardiac insufficiency. At the time of hospitalization, she was taking an antihypertensive, an anticoagulant, nitroglycerin, a long-acting nitrate, and a diuretic (among other drugs). On discharge, three weeks later, she received another long-acting nitrate, nitropaste, another diuretic, digoxin, and another antihypertensive. At home, she resumed taking her old drugs (which had been given back to her in the hospital) and started on the new drugs. Obviously, there had been no discussion of any kind as to her drug regimen. Incidentally, massive gastrointestinal upset and vomiting was then treated, after telephone discussion, with ice chips. Clearly, a pharmacist's visiting the home right after the return of the patient could have prevented these overdoses and overmedications.
The Pharmaceutical Industry
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